P3 Health Partners Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Net loss ($42.0m) ($31.4m) ($146.4m) ($1.6b) ($186.4m) ($310.4m) ($323.1m)
Depreciation and amortization $1.6m $87.3m $86.7m $86.1m $84.2m $84.2m
Amortization of original issue discount and debt issuance costs $1.8m $0 $472k $87k $13.6m
Deferred income taxes $0 ($1.1m) $2.9m $3.3m
Impairment of assets held for sale $0 $8.1m $0
Accounts payable, accrued expenses, and other current liabilities $34.2m $6.1m $16.0m ($8.1m) $11.1m $9.9m
Increase in accounts payable related to private placement offering costs $0 $12k $686k $0
Increase in accounts payable related to at-the-market offering costs $0 $19k $0
Accrued payroll $503k $2.3m ($1.1m) $1.9m $282k ($784k) ($772k)
Accrued interest $2.2m $1.8m $5.2m $5.3m $9.6m $7.9m ($1.9m)
Increase in accrued expenses related to debt issuance costs and original issue discount $525k $212k $307k $0
Increase in accrued expenses related to at-the-market offering costs $0 $206k $0
Prepaid expenses and other current assets $4.3m $4.3m ($1.2m) ($10.8m) $3.0m
Net cash used in operating activities ($28.3m)
($24.6m) +13.05%
($51.1m) -107.88%
($126.0m) -146.47%
($76.0m) +39.67%
($110.1m) -44.85%
($91.2m) +17.15%
($85.2m) +6.58%
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property $0 ($13.3m) $162k ($4.7m)
Purchases of property and equipment $1.5m $2.9m ($3.3m) ($2.2m) ($1.8m) $0 $79k ($119k)
Net cash provided by investing activities ($3.9m) ($3.2m) ($8.2m) ($7.7m) ($1.8m) $14.5m $129k $86k
Provision for bad debts $0 $3.0m
Proceeds from long-term debt, net of original issue discount $16.2m $36.4m $24.6m $15.0m $14.1m $88.1m $73.0m
Payment of debt issuance costs ($375k) $0 ($173k) ($103k) ($186k)
Repayment of short-term and long-term debt ($14.6m) ($1.5m) ($187k) ($46k) $0 ($31.0m) ($1.1m)
Proceeds from short-term debt $352k $0 $1.9m $1.1m
Warrants issued in connection with new debt $643k $0 $12.1m $26.7m
Net cash provided by financing activities $63.6m
$34.8m -45.36%
$24.8m -28.68%
$11.4m -54.12%
$100.3m +782.04%
$98.8m -1.56%
$72.8m -26.28%
$70.0m -3.92%
Cash and restricted cash, beginning of year $32.9m $39.9m $5.4m $18.5m $40.9m $44.1m $25.8m
Net change in cash and restricted cash $31.5m $7.0m ($34.5m) ($122.4m) $22.5m $3.2m ($18.3m)
Restricted cash $54k $920k $4.6m $5.3m $795k
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Equity-based compensation $474k $447k $3.7m $19.4m $6.0m $5.8m $5.6m
Paid in-kind interest expense $560k $685k $2.8m $5.7m $5.8m $7.9m $29.7m
Accretion of contingent consideration $400k $113k $0
Gain on write off of contingent consideration $0 ($4.9m) $0
Mark-to-market adjustment of stock warrants $7.7m ($9.9m) ($433k) ($22.1m) ($7.8m)
Premium deficiency reserve $6.4m ($20.5m) $11.6m ($11.5m) ($12.7m) $53.7m $18.7m
Health plan receivable ($9.7m) ($27.5m) ($2.8m) ($21.8m) ($46.6m) ($2.8m) $28.7m
Clinic fees, insurance, and other receivable ($1.5m) ($5.3m) $4.6m ($990k) ($2.3m)
Other long-term assets $100k ($58k) ($43k) ($3.5m)
Health plan settlements payable $1.9m $8.8m $11.3m ($8.9m) $21.4m $20.6m $14.3m
Claims payable $12.1m $37.1m $19.1m $49.2m $26.8m $77.1m $32.7m
Operating lease liability $306k $4.0m ($450k) $53k $641k
Other long-term liabilities $0 $5.9m $0
Proceeds from asset sale $14.5m $50k
Proceeds from liability-classified warrants and private placement offering, net of offering costs paid $0 $86.6m $40.5m $0
Proceeds from at-the-market sales, net of offering costs paid $0 $33k $0
Deferred offering costs paid $0 ($175k) ($507k) $0
Payment of tax withholdings upon settlement of restricted stock unit awards $0 ($16k) ($103k) $0
Interest Paid, Excluding Capitalized Interest, Operating Activity $560k $685k $2.8m $5.7m $5.8m $14.2m $13.6m
Income Taxes Paid $0 $567k $5.5m $1.4m
Operating lease liabilities arising from obtaining new right-of-use assets $4.1m $6.8m $7.2m $617k $361k
Operating Lease Right Of Use Assets Reduced Due To Lease Modification And Termination $0 ($92k) $0
Increase in other receivable related to at-the-market sales proceeds $0 $33k $0
Restricted stock unit awards issued in satisfaction of executive transaction bonuses $0 $5.0m $0
Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes $0 ($117.9m) ($22.8m) ($3.9m)
Fair value adjustment to redeemable noncontrolling interest $0 $20.6m ($20.6m) $119.4m
Cash $5.3m $17.5m $36.3m $38.8m $25.0m ($85.2m)

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.